William Blair Issues Positive Outlook for FibroGen Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Stock analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of FibroGen in a report released on Wednesday, November 13th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings of ($0.86) per share for the year, up from their previous estimate of ($1.12). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. William Blair also issued estimates for FibroGen’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.38) EPS.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same quarter last year, the firm earned ($0.52) EPS.

Separately, StockNews.com started coverage on shares of FibroGen in a research note on Thursday, November 14th. They issued a “hold” rating for the company.

FibroGen Stock Performance

FGEN stock opened at $0.34 on Monday. The stock has a market cap of $34.00 million, a PE ratio of -0.27 and a beta of 0.72. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93. The company has a 50-day moving average price of $0.36 and a 200 day moving average price of $0.71.

Hedge Funds Weigh In On FibroGen

A number of large investors have recently bought and sold shares of FGEN. Acadian Asset Management LLC raised its stake in shares of FibroGen by 34.4% during the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after acquiring an additional 860,854 shares in the last quarter. AQR Capital Management LLC grew its position in shares of FibroGen by 139.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of FibroGen during the third quarter valued at $307,000. XTX Topco Ltd purchased a new position in shares of FibroGen during the second quarter valued at $424,000. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of FibroGen by 3,906.9% in the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 280,161 shares in the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.